NovoCure Limited last reported quarterly results on Oct 29, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): revenue of $193.4 million (+15.7% year over year) and diluted EPS of -$0.09. It usually reports 12–30 days after a quarter ends. Based on that pattern, the next release is estimated for around Jan 11, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Monday. Based on last year's release for the same quarter on Jan 12, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 12–30 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Oct 29, 2026
29 days after quarter end
|
Q3 FY2026
ended Sep 30, 2026
|
193
+15.7%
|
-10
+72.0%
|
-0.09
+72.7%
|
|
Jul 23, 2026
23 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
184
+15.6%
|
-16
+61.0%
|
-0.13
+63.9%
|
|
Apr 30, 2026
30 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
174
+12.3%
|
-71
-107.3%
|
-0.62
-100.0%
|
|
Jan 12, 2026
12 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
174
+8.1%
|
-24
+62.8%
|
-0.22
+64.1%
|
|
Oct 30, 2025
30 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
167
+7.8%
|
-37
-21.9%
|
-0.33
-17.9%
|
|
Jul 24, 2025
24 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
159
+5.6%
|
-40
-20.3%
|
-0.36
-16.1%
|
|
Apr 24, 2025
24 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
155
+11.9%
|
-34
+11.5%
|
-0.31
+13.9%
|
|
Jan 13, 2025
13 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
161
+20.5%
|
-66
-40.0%
|
-0.61
-38.2%
|
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- NVCR (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- St. Helier
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1645113
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.